173 related articles for article (PubMed ID: 18723551)
21. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
22. Cervical carcinoma: a comparison of four potential biochemical tumor markers.
Dodd JK; Henry RJ; Tyler JP; Houghton CR
Gynecol Oncol; 1989 Feb; 32(2):248-52. PubMed ID: 2910788
[TBL] [Abstract][Full Text] [Related]
23. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma.
Bender DP; Sorosky JI; Buller RE; Sood AK
Am J Obstet Gynecol; 2003 Jul; 189(1):113-7. PubMed ID: 12861147
[TBL] [Abstract][Full Text] [Related]
24. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S
Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer.
Molina R; Filella X; Lejarcegui JA; Pahisa J; Torné A; Rovirosa A; Mellado B; Ordi J; Puig-Tintore LM; Alicarte J; Biete A; Iglesias J
Tumour Biol; 2003; 24(3):156-64. PubMed ID: 14610320
[TBL] [Abstract][Full Text] [Related]
26. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of serum squamous cell carcinoma antigen in patients with early cervical squamous cell carcinoma].
Li D; Xu XX; Yan DD; Yuan SH; Lou HM
Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):357-362. PubMed ID: 31137169
[No Abstract] [Full Text] [Related]
28. [Clinical significance of serum squamous cell carcinoma antigen in the diagnosis, treatment and prognosis of cervical squamous cell carcinoma].
Luan XM; Zhang Y; Wang SZ; Wang N; Li W; Zhang Q; Wei H; Zhang SL
Zhonghua Yi Xue Za Zhi; 2012 May; 92(19):1330-3. PubMed ID: 22883121
[TBL] [Abstract][Full Text] [Related]
29. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
Özdemir E; Çiçek T; Kaya MO
Urol J; 2012; 9(3):568-73. PubMed ID: 22903479
[TBL] [Abstract][Full Text] [Related]
30. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
31. Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure.
Bilim O; Takeishi Y; Kitahara T; Ishino M; Sasaki T; Suzuki S; Shishido T; Kubota I
J Card Fail; 2010 Nov; 16(11):873-9. PubMed ID: 21055651
[TBL] [Abstract][Full Text] [Related]
32. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.
Johansen JS; Lottenburger T; Nielsen HJ; Jensen JE; Svendsen MN; Kollerup G; Christensen IJ
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2603-8. PubMed ID: 18843001
[TBL] [Abstract][Full Text] [Related]
33. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
Gronlund B; Høgdall EV; Christensen IJ; Johansen JS; Nørgaard-Pedersen B; Engelholm SA; Høgdall C
Int J Biol Markers; 2006; 21(3):141-8. PubMed ID: 17013795
[TBL] [Abstract][Full Text] [Related]
34. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
[TBL] [Abstract][Full Text] [Related]
35. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
Kim SH; Das K; Noreen S; Coffman F; Hameed M
World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
[TBL] [Abstract][Full Text] [Related]
36. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.
Tabata T; Takeshima N; Tanaka N; Hirai Y; Hasumi K
Tumour Biol; 2000; 21(6):375-80. PubMed ID: 11006578
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of the inflammatory protein YKL-40 in precancers of the breast.
Qin W; Zhu W; Schlatter L; Miick R; Loy TS; Atasoy U; Hewett JE; Sauter ER
Int J Cancer; 2007 Oct; 121(7):1536-42. PubMed ID: 17565739
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer.
Fan JT; Si XH; Liao Y; Shen P
Arch Gynecol Obstet; 2013 Jan; 287(1):111-5. PubMed ID: 22945838
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
Abe A; Nakano T; Morita S; Oka K
Anticancer Res; 1999; 19(1B):829-36. PubMed ID: 10216501
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma.
Avall-Lundqvist EH; Sjövall K; Nilsson BR; Eneroth PH
Eur J Cancer; 1992; 28A(10):1695-702. PubMed ID: 1389488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
